advertisement
11.14 Investigational drugs; pharmacological experiments (52)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Chandrawati R
Advanced materials (Deerfield Beach, Fla.) 2017; 29:
71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Peng J
Biochemical and Biophysical Research Communications 2017; 484: 474-479
71590 Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery
Suh W
J Korean Med Sci 2017; 32: 666-671
71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Lambert WS
Frontiers in neuroscience 2017; 11: 45
71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Liu XF
Frontiers in pharmacology 2017; 8: 66
71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Maria DN
Pharmaceutical Research 2017; 34: 809-824
71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Vicente A
Ophthalmic Research 2017; 57: 201-207
71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Luo X
Journal of Neurochemistry 2017; 141: 373-386
71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Patil A
AAPS PharmSciTech 2017; 18: 2291-2302
71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Chang JY
Advanced materials (Deerfield Beach, Fla.) 2017; 29:
71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Abd-Elgawad AH
Pharmaceutical Research 2017; 34: 809-824
71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Singh S
AAPS PharmSciTech 2017; 18: 2291-2302
71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Hao JL
Frontiers in pharmacology 2017; 8: 66
71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Prud'homme S
Ophthalmic Research 2017; 57: 201-207
71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Zhou H
Biochemical and Biophysical Research Communications 2017; 484: 474-479
71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Yu Y
Journal of Neurochemistry 2017; 141: 373-386
71590 Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery
Han KE
J Korean Med Sci 2017; 32: 666-671
71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Carlson BJ
Frontiers in neuroscience 2017; 11: 45
71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Ferreira J
Ophthalmic Research 2017; 57: 201-207
71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Reina-Torres E
Advanced materials (Deerfield Beach, Fla.) 2017; 29:
71590 Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery
Han JR
J Korean Med Sci 2017; 32: 666-671
71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Formichella CR
Frontiers in neuroscience 2017; 11: 45
71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Kuang G
Biochemical and Biophysical Research Communications 2017; 484: 474-479
71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Opere C
AAPS PharmSciTech 2017; 18: 2291-2302
71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Soliman OA
Pharmaceutical Research 2017; 34: 809-824
